vs
Amphastar Pharmaceuticals, Inc.（AMPH）とMONRO, INC.（MNRO）の財務データ比較。上の社名をクリックして会社を切り替えられます
MONRO, INC.の直近四半期売上が大きい（$293.4M vs $183.1M、Amphastar Pharmaceuticals, Inc.の約1.6倍）。Amphastar Pharmaceuticals, Inc.の純利益率が高く（13.3% vs 3.8%、差は9.5%）。Amphastar Pharmaceuticals, Inc.の前年同期比売上増加率が高い（-1.8% vs -4.0%）。Amphastar Pharmaceuticals, Inc.の直近四半期フリーキャッシュフローが多い（$24.6M vs $9.1M）。過去8四半期でAmphastar Pharmaceuticals, Inc.の売上複合成長率が高い（3.2% vs -2.7%）
Amphastar Pharmaceuticalsは上場されている米国の特殊製薬企業です。2004年5月に設立され、主に吸入剤および鼻腔内投与製品の開発、生産、販売を行っており、特色ある医薬品分野で事業を展開しています。
モンロー社（Monro, Inc.）は自動車サービス企業で、創業地および本社はアメリカ合衆国ニューヨーク州ロチェスターです。2025年時点で1260店舗を展開しており、店舗数と売上高においてDriven Brandsに次ぐ北米第2位の自動車サービス企業です。
AMPH vs MNRO — 直接比較
損益計算書 — Q4 FY2025 vs Q3 FY2026
| 指標 | | |
|---|---|---|
| 売上 | $183.1M | $293.4M |
| 純利益 | $24.4M | $11.1M |
| 粗利率 | 46.8% | 34.9% |
| 営業利益率 | 19.4% | 6.3% |
| 純利益率 | 13.3% | 3.8% |
| 売上前年比 | -1.8% | -4.0% |
| 純利益前年比 | -35.7% | 143.1% |
| EPS（希薄化後） | $0.51 | $0.35 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $183.1M | $293.4M | ||
| Q3 25 | $191.8M | $288.9M | ||
| Q2 25 | $174.4M | $301.0M | ||
| Q1 25 | $170.5M | $295.0M | ||
| Q4 24 | $186.5M | $305.8M | ||
| Q3 24 | $191.2M | $301.4M | ||
| Q2 24 | $182.4M | $293.2M | ||
| Q1 24 | $171.8M | $310.1M |
| Q4 25 | $24.4M | $11.1M | ||
| Q3 25 | $17.4M | $5.7M | ||
| Q2 25 | $31.0M | $-8.1M | ||
| Q1 25 | $25.3M | $-21.3M | ||
| Q4 24 | $38.0M | $4.6M | ||
| Q3 24 | $40.4M | $5.6M | ||
| Q2 24 | $37.9M | $5.9M | ||
| Q1 24 | $43.2M | $3.7M |
| Q4 25 | 46.8% | 34.9% | ||
| Q3 25 | 51.4% | 35.7% | ||
| Q2 25 | 49.6% | 35.5% | ||
| Q1 25 | 50.0% | 33.0% | ||
| Q4 24 | 46.5% | 34.3% | ||
| Q3 24 | 53.3% | 35.3% | ||
| Q2 24 | 52.2% | 37.2% | ||
| Q1 24 | 52.4% | 35.5% |
| Q4 25 | 19.4% | 6.3% | ||
| Q3 25 | 13.2% | 4.4% | ||
| Q2 25 | 24.2% | -2.0% | ||
| Q1 25 | 21.9% | -8.1% | ||
| Q4 24 | 24.2% | 3.3% | ||
| Q3 24 | 29.8% | 4.4% | ||
| Q2 24 | 30.3% | 4.5% | ||
| Q1 24 | 27.9% | 3.3% |
| Q4 25 | 13.3% | 3.8% | ||
| Q3 25 | 9.0% | 2.0% | ||
| Q2 25 | 17.8% | -2.7% | ||
| Q1 25 | 14.8% | -7.2% | ||
| Q4 24 | 20.4% | 1.5% | ||
| Q3 24 | 21.1% | 1.9% | ||
| Q2 24 | 20.8% | 2.0% | ||
| Q1 24 | 25.1% | 1.2% |
| Q4 25 | $0.51 | $0.35 | ||
| Q3 25 | $0.37 | $0.18 | ||
| Q2 25 | $0.64 | $-0.28 | ||
| Q1 25 | $0.51 | $-0.74 | ||
| Q4 24 | $0.74 | $0.15 | ||
| Q3 24 | $0.78 | $0.18 | ||
| Q2 24 | $0.73 | $0.19 | ||
| Q1 24 | $0.81 | $0.12 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $282.8M | $4.9M |
| 総負債低いほど良い | $608.7M | $45.0M |
| 株主資本純資産 | $788.8M | $604.9M |
| 総資産 | $1.6B | $1.6B |
| 負債/資本比率低いほどレバレッジが低い | 0.77× | 0.07× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $282.8M | $4.9M | ||
| Q3 25 | $276.2M | $10.5M | ||
| Q2 25 | $231.8M | $7.8M | ||
| Q1 25 | $236.9M | $20.8M | ||
| Q4 24 | $221.6M | $10.2M | ||
| Q3 24 | $250.5M | $20.9M | ||
| Q2 24 | $217.8M | $18.7M | ||
| Q1 24 | $289.6M | $6.6M |
| Q4 25 | $608.7M | $45.0M | ||
| Q3 25 | $608.6M | $60.0M | ||
| Q2 25 | $607.7M | $71.5M | ||
| Q1 25 | $603.9M | $61.3M | ||
| Q4 24 | $601.6M | $59.3M | ||
| Q3 24 | $596.4M | $62.0M | ||
| Q2 24 | $586.9M | $112.0M | ||
| Q1 24 | $594.0M | $102.0M |
| Q4 25 | $788.8M | $604.9M | ||
| Q3 25 | $776.7M | $601.7M | ||
| Q2 25 | $757.5M | $604.9M | ||
| Q1 25 | $751.3M | $620.8M | ||
| Q4 24 | $732.3M | $648.9M | ||
| Q3 24 | $727.7M | $651.9M | ||
| Q2 24 | $713.3M | $654.4M | ||
| Q1 24 | $672.4M | $656.8M |
| Q4 25 | $1.6B | $1.6B | ||
| Q3 25 | $1.7B | $1.6B | ||
| Q2 25 | $1.6B | $1.6B | ||
| Q1 25 | $1.6B | $1.6B | ||
| Q4 24 | $1.6B | $1.7B | ||
| Q3 24 | $1.5B | $1.7B | ||
| Q2 24 | $1.5B | $1.7B | ||
| Q1 24 | $1.6B | $1.7B |
| Q4 25 | 0.77× | 0.07× | ||
| Q3 25 | 0.78× | 0.10× | ||
| Q2 25 | 0.80× | 0.12× | ||
| Q1 25 | 0.80× | 0.10× | ||
| Q4 24 | 0.82× | 0.09× | ||
| Q3 24 | 0.82× | 0.10× | ||
| Q2 24 | 0.82× | 0.17× | ||
| Q1 24 | 0.88× | 0.16× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $32.9M | $17.8M |
| フリーキャッシュフロー営業CF - 設備投資 | $24.6M | $9.1M |
| FCFマージンFCF / 売上 | 13.4% | 3.1% |
| 設備投資強度設備投資 / 売上 | 4.5% | 3.0% |
| キャッシュ転換率営業CF / 純利益 | 1.35× | 1.60× |
| 直近12ヶ月FCF直近4四半期 | $121.2M | $49.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $32.9M | $17.8M | ||
| Q3 25 | $52.6M | $32.3M | ||
| Q2 25 | $35.6M | $-1.9M | ||
| Q1 25 | $35.1M | $28.9M | ||
| Q4 24 | $29.0M | $14.8M | ||
| Q3 24 | $60.0M | $62.6M | ||
| Q2 24 | $69.1M | $25.6M | ||
| Q1 24 | $55.3M | $-5.3M |
| Q4 25 | $24.6M | $9.1M | ||
| Q3 25 | $47.2M | $26.6M | ||
| Q2 25 | $25.0M | $-9.3M | ||
| Q1 25 | $24.4M | $23.2M | ||
| Q4 24 | $16.6M | $7.9M | ||
| Q3 24 | $46.2M | $57.6M | ||
| Q2 24 | $63.1M | $16.8M | ||
| Q1 24 | $46.5M | $-11.9M |
| Q4 25 | 13.4% | 3.1% | ||
| Q3 25 | 24.6% | 9.2% | ||
| Q2 25 | 14.3% | -3.1% | ||
| Q1 25 | 14.3% | 7.9% | ||
| Q4 24 | 8.9% | 2.6% | ||
| Q3 24 | 24.1% | 19.1% | ||
| Q2 24 | 34.6% | 5.7% | ||
| Q1 24 | 27.1% | -3.8% |
| Q4 25 | 4.5% | 3.0% | ||
| Q3 25 | 2.8% | 2.0% | ||
| Q2 25 | 6.1% | 2.5% | ||
| Q1 25 | 6.3% | 1.9% | ||
| Q4 24 | 6.7% | 2.2% | ||
| Q3 24 | 7.2% | 1.6% | ||
| Q2 24 | 3.3% | 3.0% | ||
| Q1 24 | 5.1% | 2.1% |
| Q4 25 | 1.35× | 1.60× | ||
| Q3 25 | 3.03× | 5.71× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 3.23× | ||
| Q3 24 | 1.48× | 11.08× | ||
| Q2 24 | 1.82× | 4.37× | ||
| Q1 24 | 1.28× | -1.42× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
MNRO
| Tires | $150.2M | 51% |
| Maintenance | $73.5M | 25% |
| Brakes | $35.1M | 12% |
| Steering | $24.9M | 8% |
| Batteries | $6.2M | 2% |
| Exhaust | $3.2M | 1% |
